Emtricitabine
3 NDCs across 3 manufacturers|2 Generic,1 Brand
Emtricitabine is used to treat HIV infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 2, 2003, and the first generic was approved Jul 2, 2018. FDA's Orange Book lists 3 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $2 million on Emtricitabine across 5,532 claims for 974 beneficiaries.
Emtricitabine is available as 3 NDCs from 3 manufacturers (2 generic, 1 brand), with NADAC prices from $12.69 to $17.45 per EA — a 38% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
2G / 1B
Manufacturers
3
competing in market
Price Spread
$12.69 – $17.45
per EA
7d Activity
avg +1.6% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Gilead Sciences, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
3 manufacturers producing EMTRICITABINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
EMTRIVA 200 MG CAPSULE | $17.4459 per EA | — |
EMTRICITABINE 200 MG CAPSULE | $12.6867 per EA | +1.61% |
EMTRICITABINE 200 MG CAPSULE | $12.6867 per EA | +1.61% |
Frequently Asked Questions
What is Emtricitabine used to treat?
Emtricitabine is used to treat HIV infections, per the National Library of Medicine's MED-RT classification.
When did Emtricitabine become available as a generic?
FDA approved the first generic Emtricitabine (ANDA) on Jul 2, 2018. The Orange Book currently lists 3 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Emtricitabine?
In 2024, Medicare Part D spent $2 million on Emtricitabine across 5,532 claims for 974 beneficiaries.
How many Emtricitabine products are on the market?
The Emtricitabine drug market contains 3 NDCs from 3 manufacturers — 2 generic and 1 brand product.
What is the price range for Emtricitabine?
NADAC reference prices for Emtricitabine range from $12.6867 to $17.4459 per EA — a 38% difference between cheapest and most expensive.
Is generic Emtricitabine cheaper than brand?
The average generic NADAC for Emtricitabine is $12.6867 per EA, versus $17.4459 for brand-labeled products — generic is about 27% cheaper on average.
Which manufacturers make Emtricitabine?
3 manufacturers list Emtricitabine in NADAC. Ranked by number of NDCs, the largest are Gilead Sciences, Inc. (1), Aurobindo Pharma Limited (1), Cipla USA Inc. (1).
How has the price of Emtricitabine changed recently?
Over the past 7 days, 2 Emtricitabine NDCs rose and 0 fell, with a market-wide average change of +1.6%.